158 related articles for article (PubMed ID: 26170847)
21. Prognostic factors for survival in metastatic breast cancer by hormone receptor status.
Kwast AB; Voogd AC; Menke-Pluijmers MB; Linn SC; Sonke GS; Kiemeney LA; Siesling S
Breast Cancer Res Treat; 2014 Jun; 145(2):503-11. PubMed ID: 24771049
[TBL] [Abstract][Full Text] [Related]
22. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
23. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
[TBL] [Abstract][Full Text] [Related]
24. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival.
López-Guerrero JA; Llombart-Cussac A; Noguera R; Navarro S; Pellin A; Almenar S; Vazquez-Alvadalejo C; Llombart-Bosch A
Int J Cancer; 2006 Apr; 118(7):1743-9. PubMed ID: 16217770
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis.
Fokter Dovnik N; Dovnik A; Čas Sikošek N; Ravnik M; Arko D; Takač I
Breast Care (Basel); 2016 Dec; 11(6):406-410. PubMed ID: 28228707
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
27. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
29. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
30. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
31. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
32. Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China.
Cai SL; Wang ZH; Chen XG; Han L; Gong GX; Chen YP; Lin XQ; Ma T; Chen HD
Front Oncol; 2022; 12():905065. PubMed ID: 35832552
[TBL] [Abstract][Full Text] [Related]
33. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
34. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
35. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors.
Kelly PJ; Lin NU; Claus EB; Quant EC; Weiss SE; Alexander BM
Cancer; 2012 Apr; 118(8):2014-20. PubMed ID: 21918959
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.
Xiang HY; Liu YH; Zhang H; Zhang S; Xin L; Xu L; Ye JM; Li T; Duan XN; Liu Q
Chin Med J (Engl); 2019 Dec; 132(24):2914-2919. PubMed ID: 31809316
[TBL] [Abstract][Full Text] [Related]
37. A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
Yu XF; Yang HJ; Yu Y; Zou DH; Miao LL
PLoS One; 2015; 10(8):e0136670. PubMed ID: 26313461
[TBL] [Abstract][Full Text] [Related]
38. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
39. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
Matsuo S; Watanabe J; Mitsuya K; Hayashi N; Nakasu Y; Hayashi M
Breast Cancer Res Treat; 2017 Feb; 162(1):169-179. PubMed ID: 28084583
[TBL] [Abstract][Full Text] [Related]
40. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
